BioLineRx Ltd. (TLV:BLRX)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 39.16M +3.2% |
| Revenue (ttm) | 3.76M -95.9% |
| Net Income | -3.75M |
| EPS | -0.00 |
| Shares Out | 2.61B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,000 |
| Average Volume | 7,536,382 |
| Open | 1.500 |
| Previous Close | 1.500 |
| Day's Range | 1.500 - 1.500 |
| 52-Week Range | 1.100 - 3.900 |
| Beta | 0.59 |
| RSI | 54.29 |
| Earnings Date | May 26, 2026 |
About BioLineRx
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applic... [Read more]
Financial Performance
In 2025, BioLineRx's revenue was $1.18 million, a decrease of -95.92% compared to the previous year's $28.94 million. Losses were -$1.18 million, -87.26% less than in 2024.
Financial numbers in USD Financial StatementsNews
BioLineRx, Hemispherian: First patient dosed in Phase 1/2a Study of GLIX1
BioLineRx (BLRX) and Hemispherian announced that the first patient has been dosed in the first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive glioblastoma and other
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
Patient was dosed at NYU Langone Health under the supervision of Dr. Alexandra Miller, Chief of Neuro-Oncology & Co-Director of Brain and Spine Tumor Center, Perlmutter Cancer Center Data from the Pha...
BioLineRx (BLRX) Partners in Groundbreaking Glioblastoma Trial
BioLineRx (BLRX) Partners in Groundbreaking Glioblastoma Trial
BioLineRx, Hemispherian initiate clinical trial of GLIX1
Hemispherian announced the initiation of a first-in-human Phase 1/2a clinical trial of GLIX1 in patients with recurrent and progressive glioblastoma and other high-grade gliomas. The study is being co...
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
OSLO, Norway--(BUSINESS WIRE)--Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced the initiation of a first-in-human Phase 1/2a clinical t...
BioLineRx initiates Phase 1/2a study of GLIX1
BioLineRx (BLRX) announced the initiation of a first-in-human, Phase 1/2a study of GLIX1 for the treatment of recurrent and progressive GBM and other high-grade glioma. The Phase 1 part of
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
GLIX1, a TET2 activator , is a first -in- class , oral, small molecule targeting DNA damage response in glioblastoma and other cancers GLIX1 has demonstrated potent anti-tumor activity in multiple ...
BioLineRx Earnings Call Transcript: Q4 2025
GLIX1 advanced to clinical trials for glioblastoma with strong investigator enthusiasm and orphan drug status, while revenues fell sharply due to lower milestone payments. Cash reserves are sufficient into 2027, and a legal dispute was resolved favorably, removing financial risk.
Options Volatility and Implied Earnings Moves Today, March 23, 2026
Today, several major companies are expected to report earnings: Bioline RX Ltd Sponsored ADR (BLRX), Lithium Argentina (LAR), MBX Biosciences, Inc. (MBX). Ahead of earnings, TipRanks shows you the exp...
Earnings Scheduled For March 23, 2026
Companies Reporting Before The Bell • Avalo Therapeutics (NASDAQ: AVTX) is likely to report earnings for its fourth quarter. • Idaho Strategic Resources (AMEX: IDR) is projected to report quarterly ...
BioLineRx provides corporate update
“Since our last quarterly update, we have been working diligently to move forward with a Phase 1/2a first-in-human clinical trial of GLIX1 in glioblastoma, and I am pleased to report
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
- On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month - - GLIX1 is positioned to potentially address unmet needs for novel and more effecti...
BioLineRx (BLRX) and Others Set to Announce Earnings
BioLineRx (BLRX) and Others Set to Announce Earnings
BioLineRx to Report 2025 Annual Results on March 23, 2026
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, March 16, 2026 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Earnings Call Transcript: Q3 2025
A new JV was formed to develop GLIX1 for glioblastoma, with a phase I/II-A trial starting in Q1 2026 and strong patent protection secured. Q3 2025 saw $0.4M in revenue, a $1M net loss, and a $25.2M cash position, supporting operations into 2027.
BioLineRx (BLRX) Surpasses Q3 EPS Estimates Despite Revenue Shortfall
BioLineRx (BLRX) Surpasses Q3 EPS Estimates Despite Revenue Shortfall
BioLineRx (BLRX) Q3 Revenue Declines Amid New Joint Venture
BioLineRx (BLRX) Q3 Revenue Declines Amid New Joint Venture
Options Volatility and Implied Earnings Moves Today, November 24, 2025
Today, several major companies are expected to report earnings: Agilent (A), Bioline RX Ltd Sponsored ADR (BLRX), Pennantpark $ (PFLT), Semtech (SMTC), Keysight Technologies (KEYS), Blue Bird (BLBD), ...
BioLineRx reports Q3 EPS 0c vs 0c last year
Reports Q3 revenue $427k vs $4.121M last year. “The clear highlight of the third quarter was our announcement in September that we established a joint venture with Hemispherian, expanding our
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers - - Phase 1/2a clinical trial ...
Earnings Scheduled For November 24, 2025
Companies Reporting Before The Bell • Lotus Technology (NASDAQ: LOT) is likely to report earnings for its third quarter. • Qudian (NYSE: QD) is estimated to report earnings for its third quarter. • ...
BioLine Rx's Earnings: A Preview
BioLine Rx (NASDAQ: BLRX) is gearing up to announce its quarterly earnings on Monday, 2025-11-24. Here's a quick overview of what investors should know before the release. Analysts are estimating tha...
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
Management to Hold Conference Call at 8:30 a.m. EST TEL AVIV, Israel , Nov. 18, 2025 /PRNewswire/ -- BioLineRx Ltd.
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
Patent covers the use of GLIX1 for treating cancers in which cytidine deaminase (CDA) is not over-expressed (representing over 90% of cancers) Patent further broadens and strengthens GLIX1 patent prot...
BioLineRx (BLRX) and Hemispherian Collaborate on Innovative Cancer Therapy
BioLineRx (BLRX) and Hemispherian Collaborate on Innovative Cancer Therapy